Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences
Nurix Therapeutics (NRIX) and Gilead Sciences extended their oncology research collaboration by two years. Nurix will receive a $10M extension fee and could earn up to $1.3B in milestones. Nurix retains co-development and 50/50 profit-sharing options for up to two programs in the U.S.
How this was made
The 30-second read
Why it matters
The extension prolongs the collaboration timeline, adds a $10 M cash inflow, and keeps future royalty and milestone upside open.
Market read
First‑report news on a partnership extension; modest positive catalyst for NRIX, limited broader market effect.
What to watch
Future milestone payments depend on clinical success; the $10 M fee is small relative to potential $1.3 B upside.
Background
Nurix Therapeutics is a clinical‑stage biotech focused on targeted protein degradation; Gilead is a major partner with profit‑sharing rights.
Ticker impact
Nurix Therapeutics announced a second two-year extension of its research term with Gilead Sciences and received a $10 million extension fee.
likely modest upside as investors price in the $10 M fee and upside from future milestone payments.
First disclosure of the extension and fee; no immediate large cash infusion but reinforces long‑term partnership and future revenue upside.
Market effects
Highlights ongoing interest in targeted protein degradation, may benefit peers in biotech focusing on E3 ligase platforms.
US biotech sector sees a modest positive cue; no broader regional effect.
Limited to niche biotech investors; no macro impact.
Counterpoint
The extension may indicate slower progress, suggesting the partnership is not yet delivering major milestones.
Key entities
- companyNurix Therapeutics, Inc.
US‑listed biotech (NASDAQ: NRIX) receiving the extension fee.
- companyGilead Sciences, Inc.
Partner in the collaboration, not a primary subject.
